Cargando…
Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101907/ https://www.ncbi.nlm.nih.gov/pubmed/33956908 http://dx.doi.org/10.1371/journal.pone.0251671 |
| _version_ | 1783689022055383040 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8101907 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81019072021-05-17 Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer PLoS One Correction Public Library of Science 2021-05-06 /pmc/articles/PMC8101907/ /pubmed/33956908 http://dx.doi.org/10.1371/journal.pone.0251671 Text en © 2021 The PLOS ONE Staff https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title | Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title_full | Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title_fullStr | Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title_full_unstemmed | Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title_short | Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| title_sort | correction: fadraciclib (cyc065), a novel cdk inhibitor, targets key pro-survival and oncogenic pathways in cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101907/ https://www.ncbi.nlm.nih.gov/pubmed/33956908 http://dx.doi.org/10.1371/journal.pone.0251671 |
| work_keys_str_mv | AT correctionfadraciclibcyc065anovelcdkinhibitortargetskeyprosurvivalandoncogenicpathwaysincancer |